The placebo-controlled clinical study that showed Diachrome significantly improved glycemic control in patients with poorly controlled blood sugar levels who were being treated with oral anti-diabetic medication (OADs).
According to Nutrition 21, patients in the treatment group showed significant improvements in glycemic control (A1C) compared with placebo (an absolute decrease of 0.54%).
However, the greatest improvement was seen in those patients with the poorest glycemic control (baseline A1C levels equal to or greater than 10%). These patients saw an additional absolute A1C decrease of 1.76% despite the fact that they were taking one or more OAD medications.
Nutrition 21 said that the American Diabetes Association’s recommended goal for type 2 diabetes patients is an A1C level below 7.0%. The company said that lowering A1C by just 1%, especially in patients with poor blood sugar control, can delay or prevent serious complications, reduce diabetes-related deaths and reduce healthcare costs.
Nutrition 21 added that Diachrome was well tolerated and said that adverse effects and the clinical safety profile for the active group was not significantly different from the placebo.
“Uncontrolled, obese and overweight type 2 diabetes patients present an ongoing clinical challenge to health professionals. Prescribing another anti-diabetic medication can increase the risk of unwanted side effects,” said Cesar Albarracin lead investigator and a leader in the field of nutritional management of type 2 diabetes.
“This study shows that adding Diachrome to anti-diabetic medications can help patients reach their blood sugar goal simply, effectively and safely,” he concluded.